Radiation Therapy Equipment Market by Type (External Beam Radiotherapy, Internal Beam Radiotherapy), Application (Cancer, Non-cancer), End-User - Global Forecast 2024-2030

[196 Pages Report] The Radiation Therapy Equipment Market size was estimated at USD 7.76 billion in 2023 and expected to reach USD 8.28 billion in 2024, at a CAGR 7.11% to reach USD 12.55 billion by 2030.

Radiation therapy equipment is a type of medical equipment used to treat cancer and other conditions with radiation. Radiation therapy has the ability to precisely target tumors while minimizing injury to nearby healthy tissue. Radiation therapy equipment is mostly of high power and has the ability to deliver different dose levels, allowing doctors to customize treatment plans for each patient. The prevalence of cancer and the increasing adoption of surgical procedures have been the major factors driving the need for advanced radiotherapy equipment. Governments have taken multiple initiatives to expand access to cancer treatment, and improved reimbursement coverage has enabled more patients to adopt the treatment. However, the stringent government regulations regarding the approval of equipment have been impeding their penetration in many economies. Market players are consistently working on enhancing the operational abilities of radiotherapy equipment with digital and automated advancements and are maintaining the utmost quality care to ensure fast product approval. Moreover, exponential private-public investments in cancer treatment R&D are expected to encourage the development of new treatment equipment.

The Americas region observes an advanced market for radiation therapy equipment supported by the presence of established players offering highly automated equipment and developed cancer care infrastructure. The U.S. and Canada have expanded the provision of reimbursements for cancer care, which has enabled patients to access quality care with different equipment. The Asia-Pacific region observes a high prevalence of cancer cases, and medical institutes are constantly conducting R&D studies to develop improved therapies, which require new equipment. The European region has the presence of the most well-recognized players, with years of experience in offering radiotherapy equipment. Several government initiatives and awareness programs for cancer treatment have expanded the patient preference for surgeries in the early stages. The European Medical Agency and the U.S. Food and Drug Administration provide strict guidelines regarding the approval and marketing of radiotherapy equipment. However, in recent years, players have been able to achieve commercialization authorization in these countries for products that can be essential in cancer treatment.

The market dynamics represent an ever-changing landscape of the Radiation Therapy Equipment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Prevalence of cancer and increasing adoption of surgical procedures
  • Government initiatives expanding the awareness and accessibility to cancer treatment
  • Increasing availability of reimbursement coverage for cancer treatment
• Market Restraints
  • Shortage of trained oncology professionals to operate complex equipment
• Market Opportunities
  • Technological advancements in radiation therapy equipment
  • Emerging public-private investments for new cancer treatment R&D
• Market Challenges
  • Stringent equipment approval and authorization procedure

• Type: Ongoing advancements in particle therapy systems to deliver more precise radiation therapy

  External beam radiotherapy (EBRT) is a non-invasive method for providing high doses of radiation to tumors from outside the body. Conventional Cobalt-60 teletherapy units are one of the earliest forms of external beam radiotherapy equipment used in the treatment of cancer. These units operate by using gamma rays emitted from a radioactive Cobalt-60 source to destroy cancerous tissues. Linear accelerators, referred to as linacs, are the modern external beam radiotherapy. Linear accelerators deliver high-energy X-rays and electrons to the region of the patient's tumor. These devices are highly versatile, permitting a considerable degree of precision and control over the radiation dose delivered, which can be modulated to conform to the three-dimensional shape of the tumor. Particle therapy systems represent a cutting-edge and sophisticated subset of external beam radiotherapy that uses particles such as protons and heavy ions instead of X-rays to treat cancer. These systems, including proton therapy and carbon ion therapy, allow for precise delivery of radiation with a distinct physical advantage known as the Bragg peak, where the maximum energy release occurs just before the particles come to a stop within the tissue. Internal beam radiotherapy involves placing radiation sources inside and adjacent to the tumor itself. This type of therapy is necessary when a high dose of radiation is required directly at the tumor site, which is often used in the treatment of prostate, cervical, and breast cancers. Afterloaders play a pivotal role in brachytherapy, a type of internal beam radiotherapy. These sophisticated devices allow for the precise placement of radioactive sources within or adjacent to the tissue requiring treatment while minimizing exposure to healthcare personnel. Applicators are vital instruments used in brachytherapy to position radioactive sources at the treatment site. These tools come in various shapes and sizes, tailored to specific body sites and treatment protocols. Intraoperative radiotherapy systems are cutting-edge devices used to provide radiation to a tumor site during surgery. IORT systems allow for direct radiation delivery after the tumor is removed, while the surrounding healthy tissue can be temporarily displaced and protected. Seeds refer to tiny radioactive implants used in a form of brachytherapy called seed implantation. These seeds are implanted directly into the prostate gland, emitting a continuous but diminishing dose of radiation over time to destroy cancer cells.

• Application: Increasing prevalence of breast cancer drives the deployment of radiation therapy equipment

  In the treatment of blood cancers such as lymphoma, leukemia, and myeloma, radiation therapy can be used to destroy cancerous cells in the bone marrow, spleen, and other areas where the disease has spread. It can be used before a stem cell transplant to prepare the body to receive new blood-forming cells. Radiation therapy is a mainstay in breast cancer treatment. Post-surgery, it can be used to destroy any remaining tumor cells in the breast, chest wall, and axilla. In certain cases, it can be employed prior to surgery to shrink tumors and used palliatively to relieve symptoms of advanced cancer. For gastrointestinal cancers, including cancer of the stomach, colon, rectum, and pancreas, radiation therapy can be applied externally and internally. It is often used preoperatively to reduce tumor size and postoperatively to target residual cancer cells. It can also be essential for palliative care to alleviate pain, bleeding, and blockages. Radiation therapy for prostate cancer can be delivered through external beam radiation and brachytherapy. It can serve as a primary treatment and be used after surgery to treat remaining cancer. Advanced techniques such as image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT) allow for more precise targeting, minimizing damage to surrounding tissues. For lung and other respiratory cancers, radiation therapy can be a primary treatment and combined with other modalities. It is effective in managing small-cell and non-small-cell lung cancers, particularly for patients who cannot undergo surgery. Stereotactic body radiation therapy is a developed form offering high-precision treatment for smaller lung tumors. Radiation therapy is useful in treating squamous cell carcinoma and basal cell carcinoma, a type of skin cancer. It is a non-invasive remedy option that can be considered if surgery is not preferred and if the patient has other health issues that make surgery risky. Radiation therapy can be a curative treatment or used to relieve symptoms in advanced cancers. In non-cancer applications, radiation therapy equipment is used in the treatment of benign diseases, such as thyrotoxicosis and certain inflammatory disorders. The preference for radiation therapy in non-cancer treatments is based on the targeted action and capability to provide a non-invasive treatment option that can replace surgery and pharmacological interventions in some cases.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Radiation Therapy Equipment Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Radiation Therapy Equipment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Radiation Therapy Equipment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

• BEBIG Medical Join Forces to Pioneer Cancer Care Advancements in Uzbekistan

  BEBIG Medical, a company in the production of superior radiation therapy solutions, has announced its achievement in securing contracts for the supply of five HDR (High Dose Rate) brachytherapy units destined for hospitals throughout Uzbekistan, facilitated by the United Nations Office for Project Services (UNOPS). This initiative comes at a critical time for Uzbekistan, a nation with a burgeoning population of over 36 million, currently facing a rapid escalation in incidence and mortality rates of cancer, which represented 15.4% of premature deaths from non-communicable diseases (NCDs). [Published On: November 21, 2023]

• BEBIG Medical wins Multiple Contracts for HDR Brachytherapy Equipment in Indonesia

  BEBIG Medical, a provider of advanced radiation therapy products, has announced its successful acquisition of contracts to supply 6 HDR (High Dose Rate) brachytherapy units to Indonesian hospitals following a winning bid in the Ministry of Health (MOH) tender. This achievement reinforces BEBIG Medical's commitment to introducing state-of-the-art medical technology to aid cancer treatment within Indonesia, a nation with a burgeoning healthcare sector fueled by a population exceeding 270 million, increasing healthcare investments, and a rising middle-class demographic. [Published On: July 14, 2023]

• IBA and PARTICLE Initiate FLASH Proton Therapy Research Partnership

  Ion Beam Applications (IBA), a particle accelerator technology and proton therapy solutions provider, is advancing cancer treatment through a research partnership established with PARTICLE (Particle Therapy Interuniversity Center Leuven). IBA is set to equip PARTICLE's clinical Proteus ONE system with FLASH capability, empowering a vanguard of preclinical research into FLASH therapy's potential to minimize harm to healthy tissues while maintaining efficacious tumor targeting. This collaboration aims to improve radiotherapy for patients worldwide further. [Published On: June 26, 2023]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Radiation Therapy Equipment Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Radiation Therapy Equipment Market, highlighting leading vendors and their innovative profiles. These include Accuray Incorporated, Allengers Medical Systems Ltd, BEBIG Medical GmbH, Bionix LLC, BrainLab AG, Canon Inc., Carl Zeiss AG, Eckert and Ziegler AG, Elekta AB, GE HealthCare Technologies Inc., Hitachi, Ltd., IntraOp Medical Corp., Ion Beam Applications S.A., Klarity Medical & Equipment (GZ) Co., Ltd., LINEV Group, Mevion Medical Systems, Inc., MinXray, Inc., Mitsubishi Heavy Industries, Ltd., Nordion by Sotera Health LLC, Oraya Therapeutics Inc., PTW Freiburg GmbH, RefleXion Medical, Inc., Royal Philips, Siemens Healthineers AG, Stryker Corporation, Sumitomo Heavy Industries, Ltd., and Xstrahl Group.

This research report categorizes the Radiation Therapy Equipment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • External Beam Radiotherapy
    • Conventional Cobalt-60 Teletherapy Units
    • Linear Accelerators
    • Particle Therapy Systems
  • Internal Beam Radiotherapy
    • Afterloaders
    • Applicators
    • IORT Systems
    • Seeds
• Application
  • Cancer
    • Blood Cancer
    • Breast Cancer
    • Gastrointestinal Cancer
    • Prostate Cancer
    • Respiratory & Lung Cancer
    • Skin Cancer
  • Non-cancer
• End-User
  • Hospitals
  • Specialty Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?